Skip to content
ClinCalc Pro
Menu
α-blocker + antimuscarinic

Tamsulosin with solifenacin

Brand names: Vesomni

This fixed-dose combination joins the alpha-blocker tamsulosin with the antimuscarinic solifenacin for men with both voiding and storage lower urinary tract symptoms associated with benign prostatic hyperplasia.

Dosing — being independently re-sourced

ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.

Clinical monograph

How it works

Tamsulosin relaxes prostatic and bladder-neck smooth muscle through selective alpha-1A adrenoceptor blockade to ease voiding, while solifenacin blocks detrusor M3 muscarinic receptors to reduce urgency and frequency.

Prescribing in practice

  • The antimuscarinic component risks acute urinary retention, so it should be avoided where there is a significant post-void residual or high obstruction risk, and patients warned to report inability to void.
  • Combined effects include postural hypotension from tamsulosin and antimuscarinic effects (dry mouth, constipation, confusion), with caution in narrow-angle glaucoma and the elderly.
  • Tell cataract surgeons about tamsulosin use because of the risk of intra-operative floppy iris syndrome.

Monitoring

Review voiding efficiency and post-void residual alongside storage-symptom response and antimuscarinic tolerability.

Counselling the patient

  • Report any difficulty or inability to pass urine promptly.
  • Expect possible dry mouth and dizziness on standing; mention this medicine before eye surgery.

Evidence & guidelines

Trials of combined alpha-blocker and antimuscarinic therapy show improved storage symptoms over alpha-blocker alone in selected men with low retention risk.

Reference: NICE NG106; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).

Related

Curated clinical cross-links plus same-class fallbacks.